ABSTRACT
Objective We aimed to investigate cardiac effects of severe SARS-CoV-2 and the importance of echocardiography-assessment and biomarkers.
Methods This is an observational study of the first patients admitted to intensive care due to SARS-CoV-2-respiratory failure. Thirty-four underwent echocardiography of which twenty-five were included, compared to forty-four non-echo patients. Exclusion was based on absence of normofrequent sinus rhythm and/or mechanical respiratory support. Biomarkers were analysed on clinical indication.
Results Mortality was higher in the echo-compared to non-echo group (44 % vs. 16%, p<0.05). Right-sided parameters were not under significant strain. Tricuspid valve regurgitation velocity indicated how increased pulmonary pressure was associated with mortality (survivors: 2.51 ± 0.01 m/s vs. non-survivors: 3.06 ± 0.11 m/s, p<0.05), before multiple comparison-correction. Setting cut-off for pulmonary hypertension to 2.8 m/s generated p<0.01 using frequency distribution testing. Cardiac markers, high sensitivity cardiac troponin I and N-terminal pro brain natriuretic peptide, and D-dimer were higher in the echocardiography group. (hs-TnI (ng/L): echo : 133 ± 45 vs. non-echo: 81.3 ± 45, p<0.01; NT-proBNP (ng/L): echo: 2959 ± 573 vs. non-echo: 1641 ± 420, p<0.001; D-dimer (mg/L): echo: 16.1 ± 3.7 vs. non-echo: 6.1 ± 1.5, p<0.01) and non-survivor group (hs-TnI (ng/L): survivors: 59.1 ± 21 vs. non-survivors: 211 ± 105, p<0.0001; NT-proBNP (ng/L): survivors: 1310 ± 314 vs. non-survivors: 4065 ± 740, p<0.0001; D-dimer (mg/L): survivors: 7.2 ± 1.5 vs. non-survivors: 17.1 ± 4.8, p<0.01). Tricuspid regurgitation velocity was positively correlated with cardiac troponin I (r=0.93, r2=0.74, p<0.001).
Conclusions These results suggest there is no negative effect on cardiac function in critical SARS-CoV-2. Pulmonary pressure appears higher amongst non-survivors indicating pulmonary disease as the driver of mortality. Echocardiography was more commonly performed in the non-survivor group, and cardiac biomarkers as well as D-dimer was higher in the non-survivor group suggesting they carry negative prognostic values.
Trial registration number This is an observational study from patients included in “Clinical trials NCT04316884”
Strength and limitations of this study
- The patient cohort is recruited from consecutive patients admitted to the ICU in need of mechanical respiratory support independent of background which makes it relevant to clinical practice.
- The echocardiographic image acquisition was carried out by hospital assigned agents on clinical indication, which makes the results applicable in a clinical setting.
- Since the image acquisition was carried out on a clinical indication, the results may be skewed towards the false positive if applied to all Covid19 patients.
Competing Interest Statement
ML: DSM board member for PROFLO multicenter randomized clinical trial ISRCTN54917435 DSM board member for COVID-19-HBO, EudraCT no: 202020-001349-37 Member of the prioritizing committee for Sjukvardsregionala forskningsradet Mellansverige a research fund https://www.sjukvardsregionmellan.se/om-oss1/ HI: Has received speaker honoraria from AstraZeneca from an unrelated area.
Funding Statement
This study was supported by grants from the Swedish Society for Medical Research, the Swedish Research Council, and SciLife/Knut and Alice Wallenberg Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a sub-study of the single-centre, prospective observational investigation PronMed study, approved by the Swedish National Ethical Review Agency, Dnr 2017-043 (with amendments 2019-00169, 2020-01623, 2020-02719, 2020-05730, 2021-01469) and Dnr 2022-00526-01.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Due to Swedish and European privacy laws individual level data cannot be shared publicly but data are available after securing appropriate ethical permissions and data transfer agreements.
